Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 7,881 matching trials from the live ClinicalTrials.gov search.
Conditions
Fibrosing Colonopathy
Interventions
ULTRESA, PANCREAZE, CREON, ZENPEP, other non-sponsor pancreatic enzyme replacement therapy, PERTZYE, No pancreatic enzyme replacement therapy
Biological · Other
Lead sponsor
AbbVie
Industry
Eligibility
0 Months to 99 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
123
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 102 more
Conditions
HIV Infections
Interventions
Thalidomide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
6
States / cities
Aurora, Colorado • Minneapolis, Minnesota • New York, New York + 3 more
Conditions
Peripheral Nerve Injuries
Interventions
Processed Human Nerve Graft, Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc., Autogenous Nerve Graft, Nerve Tube Conduit, Autologous Breast Reconstruction with Neurotization, Autologous Breast Reconstruction without Neurotization
Other · Device · Procedure
Lead sponsor
Axogen Corporation
Industry
Eligibility
Not listed
Enrollment
3,126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2028
U.S. locations
46
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 33 more
Conditions
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, External Beam Radiation Therapy, Filgrastim, Isotretinoin, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate Liposome
Procedure · Drug · Radiation + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
169
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 128 more
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
FATE-NK100, Interleukin-2
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
SCID
Interventions
Humanized anti-CD117 Monoclonal Antibody (JSP191)
Biological
Lead sponsor
Jasper Therapeutics, Inc.
Industry
Eligibility
3 Months to 12 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 6 more
Completed Phase 2 Interventional Results available

Tocilizumab (TCZ) in New-onset Type 1 Diabetes

NCT02293837
Conditions
Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus, T1DM, T1D
Interventions
Tocilizumab (TCZ), Placebo, Standard of Care
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 17 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
17
States / cities
San Francisco, California • Stanford, California • New Haven, Connecticut + 14 more
Conditions
Central Nervous System Neoplasm, Pineoblastoma, Recurrent Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor, Refractory Medulloblastoma, Refractory Peripheral Primitive Neuroectodermal Tumor
Interventions
Bevacizumab, Irinotecan Hydrochloride, Temozolomide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
136
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 103 more
Conditions
Prostate Cancer
Interventions
99mTc-MIP-1404 Injection, Whole-Body Planar and pelvic SPECT/CT scan
Drug · Diagnostic Test
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
33
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 26 more
Completed No phase listed Observational

Stem Cell Related Donor Safety Study

NCT00948636
Conditions
Related Hematopoietic Stem Cell Donors
Interventions
Not listed
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
Not listed
Enrollment
1,812 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
52
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 44 more
Conditions
Waldenström Macroglobulinemia (WM)
Interventions
Acalabrutinib (ACP-196)
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
10
States / cities
Santa Barbara, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
Conditions
Gaucher Disease Type I, Oxidative Stress, Inflammation
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Phase 1 Interventional Accepts healthy volunteers

Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL

NCT03019666
Conditions
Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mantle-Cell Lymphoma, Follicular Lymphoma, Indolent B Cell Lymphoma, Primary Mediastinal Lymphoma, Lymphoplasmacytic Lymphoma
Interventions
Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Recurrent or Refractory Pediatric Ependymoma
Interventions
erlotinib, etoposide
Drug
Lead sponsor
OSI Pharmaceuticals
Industry
Eligibility
1 Year to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 14 more
Conditions
End Stage Renal Disease, Kidney Disease, Protein Energy Wasting
Interventions
PINTA 745, Placebo
Drug
Lead sponsor
Pinta Biotherapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 3 more
Conditions
Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissue, Metastatic Malignant Neoplasm in the Viscera, Rhabdoid Tumor of the Kidney, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
858
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 554 more
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tofimilast
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
23
States / cities
Phoenix, Arizona • Riverside, California • Clearwater, Florida + 18 more
Conditions
Lung Cancer
Interventions
filgrastim, carboplatin, etoposide, paclitaxel, topotecan hydrochloride, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
48
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more
Conditions
Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With, Glucocorticoid-induced Osteoporosis
Interventions
Denosumab, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
5 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Wilmington, Delaware • Indianapolis, Indiana + 3 more
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
62
States / cities
Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 57 more
Conditions
Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
Interventions
Aplitabart (IGM-8444), FOLFIRI, Bevacizumab (and approved biosimilars), Birinapant, Venetoclax, Gemcitabine, Docetaxel, Azacitidine
Drug
Lead sponsor
IGM Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
37
States / cities
Phoenix, Arizona • Duarte, California • Los Alamitos, California + 29 more
Conditions
Type 1 Diabetes, Eating Disorder
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
12 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
IMC-1121B (ramucirumab), Pemetrexed, Carboplatin (AUC 6), Cisplatin, Gemcitabine, Carboplatin (AUC 5)
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
38
States / cities
Scottsdale, Arizona • Tucson, Arizona • Corona, California + 35 more
Conditions
Status Epilepticus
Interventions
Intramuscular route of active treatment, Intravenous route of active treatment
Drug
Lead sponsor
Robert Silbergleit
Other
Eligibility
Not listed
Enrollment
1,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
17
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 12 more